To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

January 18, 2019

Today's Rundown

Featured Story

Celgene strikes Obsidian deal to boost CAR-T options 

Celgene is pushing ahead with its immuno-oncology dealmaking program while working toward its $74 billion takeout by Bristol-Myers Squibb. The big biotech ended the week by expanding its CAR-T toolkit via a deal with Obsidian Therapeutics and placing an $80 million bet on Kyn Therapeutics.

Top Stories

Novartis allies with Oxford academics for big data R&D drive

Novartis has teamed up with the University of Oxford to use artificial intelligence to improve drug development. The collaboration will analyze MRI data from 35,000 multiple sclerosis patients and results from IL-17 inhibitor trials to better understand diseases important to Novartis’ prospects.

Apple, J&J to put the Apple Watch’s ECG through large-scale clinical testing

Apple and Johnson & Johnson are teaming up on a multiyear research study to see if the latest Apple Watch can help catch and diagnose elderly people with atrial fibrillation earlier and faster than before.

Former Insmed CMO Streck resurfaces at Alder

A few days after leaving Insmed to take up an “employment opportunity on the West Coast,” Paul Streck has popped up at migraine specialist Alder BioPharmaceuticals.

On heels of Loxo buy, Lartruvo setback deals a blow to Lilly's oncology hopes

Eli Lilly agreed to shell out $8 billion last week for Loxo Oncology in a deal executives billed as a boost for its cancer goals. Good thing, too, given a Friday setback for soft tissue sarcoma drug Lartruvo, which failed a phase 3 trial—so much so that Lilly will stop promoting the drug.

EuroBiotech Report—EMA-Brexit, AstraZeneca, Juvenescence round, Verona fail and Orchard

In this week's EuroBiotech Report, EMA raises staff retention forecast, Berman swaps AstraZeneca for Immunocore and Juvenescence raises $46 million.

FiercePharmaAsia—Gilead’s clinical VP; Aurobindo buys Spectrum assets; Aslan’s lead drug

Gilead loses its vice president of clinical research to NASH-focused Terns; Spectrum unloads its marketed portfolio to India's Aurobindo in a deal worth $300 million; Aslan's lead drug varlitinib misses the mark in a gastric cancer trial; and more.

Chutes & Ladders—Exoduses continue at AstraZeneca

CMO Sean Bohen and I-O head David Berman are leaving AstraZeneca, while Roche's Omar Khwaja and Pearl Huang land at new biotechs. Those moves plus more hirings, firings and retirings throughout the industry.

Enrollment Showcase

Online Graduate Programs Designed for Your Career

Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more.

Resources

[Whitepaper] Accelerate Time To Market Working With Industry Specialist MSP

With FDA approval imminent, start-up Life Sciences company partners with an industry focused MSP to design and manage its regulated cloud-based infrastructure to speed time to market.

[Whitepaper] Liquid Biopsy Investor Toolkit

With the liquid biopsy market maturing and >80 companies still competing with liquid biopsy offerings, it is crucial for investors to be able to cut through the noise and identify the winners.

[Survey] Veeva 2019 Unified Clinical Operations Survey

Share your thoughts on the life sciences industry's progress in improving study execution.

[Whitepaper] The 3DP Revolution: Planning Effective Brand Extension for In-Market Drugs

Get ahead of looming challenges in the market that include both generic products and new branded drugs.

[Infographic] Clinical Development Trends And The Impact On Clinical Trial Technology

New infographic shows trends in clinical development and the impact on randomization and trial supply management technology (RTSM).

[Webinar] Building the Business Case for Transformational RIM

Reduce the effort to create submissions and track registrations with a move to unified RIM. Watch the on-demand webinar.

[eBook] 2018 Weekly Compendium

The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry.

Events